Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Trump Says Anthropic No Longer Seen as National Security Threat 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Dublin, Dec. 07, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/763qfd/nitric_oxide) has announced the addition of Jain PharmaBiotech's new report "Nitric Oxide - Therapeutics, Markets and Companies" to their offering.
This report Analyses the latest concepts of nitric oxide (NO) and the role it plays in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric oxide-based drugs are described as well as the companies involved in developing them.
Various pharmacological approaches are described along with their therapeutic relevance. Various approaches are compared using SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis. NO-based therapies are compared with conventional approaches and opportunities for combination with modern biotechnology approaches are described.
Share of drugs where NO is involved in the mechanism of action is analyzed in the worldwide pharmaceutical market for 2014 and is projected to 2019 and 2024 as new drugs with NO-based mechanisms are introduced into the market. Various strategies for developing such drugs are discussed.
Several companies have a product or products involving NO and free radicals. The report includes profiles of 34 companies involved in this area of which 8 have a significant interest in NO-based therapeutics. Other players are pharmaceutical and biotechnology companies as well as suppliers of products for NO research. Unfulfilled needs in the development of NO-based therapeutics are identified. Important 15 collaborations in this area are tabulated.
There are numerous publications relevant to NO. Selected 500 references are included in the bibliography. The text is supplemented with 25 tables and 26 figures.It is concluded that the future prospects for NO-based therapies are bright and fit in with biotechnology-based approaches to modern drug discovery and development. It is anticipated that some of these products will help in meeting the unfulfilled needs in human therapeutics.
Key Topics Covered:
Executive Summary
1. Introduction
2. Nitric Oxide Pathways
3. Role of NO in Physiology
4. Role of NO in Diseases
5. Pharmacology of Nitric Oxide
6. Therapeutic Applications
7. Evaluation of NO-Based Drugs
8. Markets for NO-based Therapies
9. Companies
10. References
For more information visit http://www.researchandmarkets.com/research/763qfd/nitric_oxide
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices
